Atthe early stage of type 1 diabetes, C-peptide replacement was shown to resultin diminished urinary albumin excretion rate and ameliorates nerve dysfunction [8].In the light of these data, fulminant type 1 diabetes couldprovide an ideal setting to explore whether C-peptide administration benefitspatients with diabetes in reducing microangiopathy. Here, ALB is linked to type 1 diabetes mellitus.